Asco 2020 virtual scientific program
Iovance Biotherapeutics
The virtual scientific program of the American Society of Clinical Oncology (ASCO) will be held May 29-31, 2020. H. Lee Moffit Cancer Center’s TIL data from Phase 1 lung cancer study presented at American Association for Cancer Research (AACR) Virtual Annual Meeting I
Overview | NantHealth
In June, announced the publication of four abstracts in the developmental therapeutics session of the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. In collaboration with ImmunityBio, LLC, the company presented data, gathered from its database, which was used to advance findings in molecularly targeted agents and ...
Investor Relations — Kura Oncology, Inc.
The Company is presenting these data at the American Society of Clinical Oncology (“ASCO”) Virtual Scientific Program being held May 29-31, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ir.cytomx.com
Data from the Phase 1 study of CX-2009 in patients with HER2 negative breast cancer were presented at the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program in May and will be updated at San Antonio Breast Cancer Conference later this year . ... 2020, compared to $10.7 million for the three months ended September ...
ir.mersana.com
Reported positive interim data from expansion portion of the XMT-1536 Phase 1 study at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. In May 2020, the Company reported interim safety, tolerability and efficacy data from the.
TRACON Pharmaceuticals Inc
On May 14, 2020, the Company issued a press release announcing the presentation of positive clinical data for envafolimab at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program by the Company’s partners 3D Medicines and Alphamab.
MacroGenics, Inc.
tetravalent DART® molecule binding PD-1 and LAG-3, and the Phase 1 dose expansion study of MGC018, an antibody-drug conjugate (ADC) targeting B7-H3, will be presented at the American Society of Clinical Oncology (ASCO) upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020.
Biocept Inc.
Presented data affirming the ability of the Target Selector™ platform to identify potentially actionable mutations in the cerebrospinal fluid of patients whose cancer has metastasized to the central nervous system at the American Society for Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
Mersana Therapeutics
The Company will present interim data from the XMT-1536 Phase 1 expansion study on a live conference call and webcast on Wednesday, May 27, 2020 at 8 a.m. ET and during a poster session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program scheduled for May 29 – 31, 2020.
AVEO Oncology
The results, which have been submitted to the U.S. Food and Drug Administration (FDA) as part of the Company’s New Drug Application (NDA) submitted in March, are being featured today at the ASCO 2020 Virtual Scientific Program in a poster titled, “TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label ...
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Hot searches
- basic programming software free download
- what are the roaring 20 s
- quality in nursing practice
- auto repair finance programs
- deep muscle massage near me
- residual torque vs dynamic torque
- erectile dysfunction pills with nitrates
- better business bureau canada search
- pregnancy nutrition handout pdf
- influenza a isolation type